Steven Cohen Revance Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $79,515 - $159,201	17,100 New	17,100 $84,000
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $7.88 Million - $17.2 Million	686,735 Added 101.52%	1,363,168 $15.6 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $16.7 Million - $25.4 Million	676,433 New	676,433 $17.1 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $2.09 Million - $3.7 Million	-181,393 Reduced 23.05%	605,574 $8.37 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $1.17 Million - $1.92 Million	-94,515 Reduced 10.72%	786,967 $15.3 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $1.58 Million - $3.53 Million	126,682 Added 16.78%	881,482 $14.4 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $19.5 Million - $25.1 Million	754,800 New	754,800 $21 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $7.19 Million - $8.55 Million	-268,400 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $6.45 Million - $8.04 Million	268,400 New	268,400 $7.5 Million
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $3.3 Million - $7.38 Million	-265,199 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $548,533 - $947,936	47,044 Added 21.56%	265,199 $4.3 Million
Q3 2019 Nov 15, 2019	BUY	$10.22 - $14.5 $1.05 Million - $1.49 Million	102,455 Added 88.55%	218,155 $2.84 Million
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $1.23 Million - $1.79 Million	115,700 New	115,700 $1.5 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.